secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001453687-25-000140
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 5.05, 7.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise
--------------------------------------------------------------------------------

- Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
- Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.
- Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.
- CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.
- Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/0001453687-25-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/rnac-20251216.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer